A phase I/II single-centre double-blinded randomized study of the safety and tolerability of TMC120 [dapivirine] vaginal microbicide gel (TMC120 Gel-002) vs. HEC-based universal placebo gel in healthy HIV-negative women

Trial Profile

A phase I/II single-centre double-blinded randomized study of the safety and tolerability of TMC120 [dapivirine] vaginal microbicide gel (TMC120 Gel-002) vs. HEC-based universal placebo gel in healthy HIV-negative women

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Dapivirine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top